Individual Treatment Effects: From Research to Action

During the next few years, a substantial number of comparative effectiveness research (CER) studies will examine a treatment’s effect on the average population, which may not apply to everyone. That’s because a treatment that is effective for most of the population may not be effective for all patients. So how should comparative effectiveness research be funded, prioritized and conducted so that these individual treatment effects (also known as heterogeneity) can be considered?

NPC logo

During the next few years, a substantial number of comparative effectiveness research (CER) studies will examine a treatment’s effect on the average population, which may not apply to everyone. That’s because a treatment that is effective for most of the population may not be effective for all patients. So how should comparative effectiveness research be funded, prioritized and conducted so that these individual treatment effects (also known as heterogeneity) can be considered?

Join NPC and a panel of experts on Sunday, June 3 at 6:30 pm as they explore this question during an engaging symposium, Individual Treatment Effects: From Research to Action. The symposium is part of the International Society for Pharmacoeconomics and Outcomes Research 17th International Annual Meeting being held at the Washington Hilton in Washington, DC.

The symposium features: 

  • Michael S. Lauer, MD, FACC, FAHA, Director, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, and Member, Patient-Centered Outcomes Research Institute Methodology Committee
  • David Meltzer, MD, PhD, Director, Center for Health and the Social Sciences, and Chief, Section of Hospital Medicine and Associate Professor, Department of Economics, Graduate School of Public Policy Studies, University of Chicago
  • Robert S. Epstein, MD, MS, former Chief Medical Officer and President, Medco Research Institute, Medco Health Solutions, Inc.
  • Moderator: Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council

Registration for ISPOR is required to attend the symposium. NPC also plans to tweet during the symposium, so be sure to follow us on Twitter @npcnow and use the hashtag #ISPORdc. See you there!